#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Leukocyte adhesion deficiency type I Von Hippel-Lindau disease Sjogren's syndrome Immune-mediated myositis Extra-osseous Ewing's sarcoma recurrent Interstitial lung disease Multiple system atrophy Uveal melanoma T-cell type acute leukaemia Small cell lung cancer extensive stage Ventricular tachycardia Chorioretinitis Stress cardiomyopathy Wolfram syndrome Gastrointestinal neuroendocrine tumour More trials…

    Learn about Rare Diseases

    KBG syndrome – Diagnostics Castleman’s disease – Treatment Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Basic Information Pleural mesothelioma malignant – Trials in Disease Antithrombin III deficiency – Trials in Disease Breast angiosarcoma – Life with Disease Propionic acidaemia – Treatment Mastocytosis – Basic Information Angiosarcoma metastatic – Treatment Pituitary-dependent Cushing’s syndrome – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Dexamethasone Tenofovir Disoproxil Fumarate Volrustomig Anakinra Azd5004 [18F]CPFPX Dexrazoxane AVTX-009 Sugammadex 68Ga-Nota-Abscint-Her2 Mosaic Hbcoreag Glimepiride BENZYLPENICILLIN POTASSIUM Nicotinamide Annamycin Bi 706321 Dexibuprofen Methylprednisolone Pralatrexate Sodium Thiosulfate More therapies…

    Learn about Your Condition

    Hepatic angiosarcoma Suicidal ideation Pyoderma gangrenosum Anal abscess Post-traumatic stress disorder Dystonic tremor Thrombosis prophylaxis Aortic aneurysm Peritoneal abscess Biotinidase deficiency Bronchiolitis Rubella Testicular germ cell cancer Rectal cancer Sarcoma metastatic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone-refractory prostate cancer

  • A study of JNJ-78278343 and docetaxel compared to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Docetaxel
    • Prednisone
    Belgium France Germany Italy Spain

  • A study evaluating the efficacy and safety of inavolisib and enzalutamide in patients with metastatic castration-resistant prostate cancer

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Inavolisib
    • Abiraterone
    • Docetaxel
    France Germany Italy Spain

  • Study of AMO959, lutetium (177Lu) vipivotide tetraxetan, and a drug combination for adults with advanced prostate cancer.

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • AMO959
    • Relugolix
    • Degarelix
    France Germany Italy Spain

  • A Study to Find a Safe Dose of TD001 for Patients with Metastatic Castration-Resistant Prostate Cancer that Expresses PSMA

    Recruiting

    2 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    France Spain

  • A Study of Tulmimetostat and Luxdegalutamide Compared to Standard Treatment in Men with Advanced Prostate Cancer That No Longer Responds to Hormone Therapy

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Tulmimetostat
    • LUXDEGALUTAMIDE
    • Abiraterone
    Denmark France Germany Italy Poland Spain

  • A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

    Recruiting

    3 1
    Belgium France Germany Italy The Netherlands Poland +1
1 2 3 … 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!